June 2nd 2024
Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Book Profiles 32 Women Who Fought Breast Cancer
October 1st 1996BIRMINGHAM, Ala--In 1994, the Comprehensive Cancer Center of the University of Alabama at Birmingham commissioned photojournalist Melissa Springer to create an exhibit celebrating breast cancer survivors. Her finished project has now been published as A Tribe of Warrior Women.
New RIA Blood Test Predicts Breast Cancer Recurrence
October 1st 1996CHICAGO--The Truquant BR RIA blood test (manufactured by Biomira Diagnostics, Inc.) has been shown to be a highly specific predictor of recurrent breast cancer. In clinical trials, positive test results predicted relapse 83% of the time, providing as much as a 12-month (average, 5 month) warning over clinical symptoms and/or other diagnostic methods for breast cancer recurrence.
New Cancer Gene Marker Could Help Tailor Chemotherapy for Breast Cancer
October 1st 1996Researchers at Duke University Comprehensive Cancer Center have found that a newly identified liver cancer gene is also defective in more aggressive breast tumors that may not respond to certain common types of chemotherapy.
Media Attention to Prostate Cancer Lags Behind Breast Cancer, Advocate Says
October 1st 1996NEW YORK--Michael Korda, best-selling author and editor-in-chief and vice president of Simon and Schuster, had never heard of PSA until a routine test showed that his was elevated; he had never thought about prostate cancer as something that could happen to him. After all, he was asymptomatic, a "fanatic exerciser," had given up smoking 20 years ago, and ate carefully.
Women, Kids from the Heartland Express Feelings about Breast Cancer
October 1st 1996OKLAHOMA CITY--Project Wo-man, a committee of the American Cancer Society (ACS)--has published a book depicting the experiences of Oklahoma women with breast cancer as expressed by the women themselves, their friends, children, and other loved ones through stories, photographs, and artwork (see illustrations at right and on page 1).
Kopans Receives the Kushner Writing Award
October 1st 1996BETHESDA, Md--Daniel B. Kopans, MD, of the Department of Radiology, Massachusetts General Hospital and Harvard Medical School, has received the 1996 Rose Kushner Award for Writing Achievement in the Field of Breast Cancer for best scientific article.
Tamoxifen Prevention Study Enrollment Nears Completion
October 1st 1996BETHESDA, Md--The Breast Cancer Prevention Trial (BCPT), launched in 1992, will need fewer women than originally estimated for completion. Although planned for 16,000 women, the trial now has more than 12,000 enrolled, and needs only another 1,000 for completion, which is expected next year.
Assessing Women's Potential Risk of Developing Breast Cancer
October 1st 1996This well-written article can benefit only from reinforcement of a few of its major points, some supplemental discussion about the important role of biologic models in understanding and managing breast cancer development, and a note about the critical need for research and perspectives from the social sciences concerning this subject. I say "only" because this article beautifully and clearly explores some of the language of epidemiology critical to the subject, language which is becoming increasingly important in routine medical practice. Practitioners and, increasingly, the public (medical "consumers") are concerned with risks and numbers.
Optimal Duration of Tamoxifen Requires More Investigation
October 1st 1996An expert panel of nine international cancer researchers and practicing oncolo-gists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. This article represents the first in a series of reports based on the symposium presentations that will be featured in subsequent issues of Oncology News International.The symposium was sponsored by Zeneca Pharmaceuticals.
Amy Langer on Leave of Absence From NABCO After Automobile Accident
October 1st 1996NEW YORK--Amy S. Langer, of the National Alliance of Breast Cancer Organizations (NABCO), has taken a leave of absence from her position as executive director, due to extensive injuries suffered in a serious car accident in upstate New York.
M.D. Anderson Unveils Mammography Van
October 1st 1996HOUSTON--Just in time for Breast Cancer Awareness Month, The University of Texas M.D. Anderson Cancer Center has unveiled a mobile mam-mography program that will bring screening mammography to corporate and community locations throughout the Houston area.
AgeAwareness Group Urges the Media to Keep Breast Cancer Issues on the Public Agenda
September 1st 1996NEW YORK--Public discussion has played a large part in the recent declines in breast cancer mortality, say the sponsors of National Breast Cancer Awareness Month (NBCAM), and they urge the media to keep breast cancer on the public agenda.
FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer
September 1st 1996ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.
Mandated ABMT Coverage May Not Lead to More Procedures
September 1st 1996PHILADELPHIA--A Massachusetts study suggests that legislation requiring insurers and HMOs to cover high-dose chemotherapy/autologous bone marrow or stem cell transplantation for metastatic breast cancer does not lead to significant increases in the number of procedures performed.
Health Insurance: Coverage of Autologous Bone Marrow Transplantation for Breast Cancer
September 1st 1996Rapid advances in biomedical research and technology are producing a continuous stream of new, and often expensive, medical devices, drugs, and therapies. Health insurers' decisions about whether and when to provide coverage for these new
Study Advocates Breast Ultrasound Screening as an Adjunct to Mammography
August 1st 1996With improved instrumentation and scanning techniques, breast ultrasound screening is earning a prominent role in the detection of breast cancer in women with dense breasts when no lump is felt and no abnormalities are detected on the
NCI Says Long-Awaited Long Island Breast Cancer Study Now Underway
August 1st 1996BETHESDA, Md--The Long Island Breast Cancer Study Project, ordered by Congress in 1993, is now underway under the auspices of the NCI and the National Institute of Environmental Health Sciences. The study will attempt to determine whether pollutants (pesticides and other chemical irritants) are linked to the area's excessive breast cancer rates.
Practice Guidelines May Lead to Fewer Malpractice Suits
August 1st 1996PHILADELPHIA--At Long Beach Community Medical Center, the addition, in 1993, of a new radiation therapy facility and a new cancer center spurred the development of clinical pathways (or practice guidelines) for radiation therapy and breast cancer.
More Insurers Covering ABMT, Despite Lack of Efficacy Data
July 1st 1996WASHINGTON--A General Accounting Office (GAO) report has found that more insurers are now covering autologous bone marrow transplants (ABMT) for patients with breast cancer even though the treatment is expensive and the benefits are not proven.
Taxotere for Anthracycline Refractory Advanced Breast Cancer
July 1st 1996COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) is now available for treatment of patients with locally advanced or metastatic breast cancer that has progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy.
ODAC Recommends Approval of Aredia for Breast Cancer Bone Mets
July 1st 1996GAITHERSBURG, Md--The FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously to recommend approval of Ciba-Geigy Corp.'s Aredia (pamidronate disodium for injection) for the treatment of osteolytic bone metastases in breast cancer patients undergoing either chemotherapy or hormonal therapy.
Radiologist Most Likely Target in Breast Cancer Lawsuits
July 1st 1996DALLAS--In the last 5 years, radiologists have become the specialists most often sued over breast cancer diagnoses, said Cathy R. Bowerman, JD, MPH, of the Southfield, Michigan, firm of Siemion, Huckabay, Bodary, Padilla, Morganti, & Bowerman.
RODEO Breast MRI Promising in Lobular Cancer Diagnosis
July 1st 1996DALLAS--RODEO breast MRI proved significantly more accurate than mammography in determining the extent of lobular carcinoma and in characterizing the morphology of the disease, Steven E. Harms, MD, said at the American College of Radiology breast cancer symposium.
Defining the Role of Post-Mastectomy Radiotherapy: The New Evidence
July 1st 1996It is ironic that the issue of aggressive local therapy for breast cancer has re-emerged as a controversial issue in the early 1990s, almost 100 years after Halsted proposed this theory in the early 1890s [1]. Since that time, both survival and quality of life seemed to have improved for patients with breast cancer, due to more sophisticated and effective treatments. Nonetheless, as Drs. Pierce and Lichter point out in their article, the precise balance between the benefits and risks of aggressive local therapy still remains to be defined.
New Aromatase Inhibitor Compared With Megestrol in Advanced Breast Cancer
June 1st 1996Results of a phase III multicenter European study reported in a recent issue of the European Journal of Cancer demonstrate that anastrozole (Arimidex), a new aromatase inhibitor, in doses of 1 and 10 mg orally once daily, is an effective treatment for
BRCA2 Gene Mutations Linked to Ovarian Cancer Cases
June 1st 1996WASHINGTON--University of Pennsylvania researchers have obtained the first "conclusive" evidence linking mutations in the recently cloned BRCA2 breast cancer gene to ovarian cancer, a discovery they say indicates that inheritance plays a significantly greater role in the disease than previously thought.
Study Finds a Link Between Fatty Acid Ratios and Breast Cancer
June 1st 1996WASHINGTON--A study of European women suffering from breast cancer has raised the intriguing possibility that the ratio of omega-3 to omega-6 polyunsaturated fatty acids (PUFA) may provide a way to predict an increased risk of the malignancy.